Sagent Pharmaceuticals, Inc. (SGNT) Tops Q2 EPS by 7c; Cuts FY12 Sales Outlook
Tweet Send to a Friend
Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT) reported Q2 EPS of ($0.17), $0.07 better than the analyst estimate of ($0.24). Revenue ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
